XTALPI

2228
5.5255.88% ( -0.345 )
Delay Closed: Nov 16, 16:08:11

Overview

XTALPI (2228)

XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally. The company offers XmartChem, an inte...

Open
5.850
High
5.850
Low
5.430
Prev. Close
5.870
Volume
57.60M
Turnover
318.76M
Avg Price
5.534
Bid/Ask Ratio
55.88%
Amplitude
7.16%
52wk High
14.280
Volume Ratio
1.12
Turnover Ratio
1.34%
52wk Low
5.430
HK Mkt Cap
23.74B
Market CapHKD
23.74B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.0565
EPSDynamic
-0.135
EPSStatic
--
BVPS
2.41
P/B
2.29
HK Shares
4.30B
Dividend YieldTTM
--
DividendTTM
--
Shares
4.30B
Min lot size
1,000
Currency
HKD

XTALPI Analyst Rating

View more

Forecast & Rating

Sep 16, 2026
Price forecast
HK$9.9379.79%
Forecast & RatingBuy
8analysts
  • Strong buy62.50%
  • Buy12.50%
  • Hold25.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    XtalPi fell 5.7% to HK$5.535 in a spike-and-fade session that printed a fresh 52-week low of HK$5.43 at 10:48 BJ, with the HK$5.85 open marking the day's high and turnover reaching HK$313.4 million at a 1.32% turnover rate. The drag is fundamental: Q2 2026 revenue of HK$227.3 million fell 19.76% year on year, the operating loss reached HK$225.1 million, net loss was HK$145.5 million on a -64% net margin, with EPS of -HK$0.0356 and a PE of -97.9x. The stock has repeatedly probed 52-week lows since the share buyback was cancelled, and a roughly HK$25 million chairman purchase at range lows failed to stop the slide. It is down 44.6% year to date, 61.2% below the 52-week high of HK$14.28, and trades under the MA20 of HK$6.09 and MA60 of HK$6.94, only 1.9% above the 52-week low. Though Q2 revenue edged above Q1's HK$223.7 million and the net loss was broadly flat versus HK$143.2 million.

  2. Nov, 12

    XtalPi (2228.HK) opened at HK$6.34 and faded through the session, touching HK$5.935 in the afternoon before closing at HK$6.04, down 5.1% from HK$6.365, on 48.5 million shares and HK$299 million turnover (1.13% turnover rate); the intraday high of HK$6.365 was set at 11:01 in the morning session. No fresh catalyst emerged, and the stock is still absorbing the October cancellation of its share buyback; it hit a 52-week low of HK$5.60 on 22 October and now trades just 7.86% above that level but 57.7% below its 13 January high of HK$14.28, down 39.54% year-to-date and below both MA20 (HK$6.109) and MA60 (HK$7.009). Fundamentals offered little support: Q2 2026 revenue fell 19.76% yoy to HK$227.3 million while the net loss widened 420.7% to HK$145.5 million, a -64% net margin and EPS of -HK$0.0356, against a PB of 2.50 and market capitalisation of HK$25.95 billion. A HK$25 million chairman purchase has not reversed the drift, though the close came off the HK$5.935 low rather than at the session bottom.

  3. Nov, 9

    AI-drug-discovery news lifted XTALPI (2228.HK) to a 6.450 HKD gap-up open, but the stock peaked at 6.425 HKD by 09:42 BJ and then faded through the afternoon to 6.210 HKD at 15:56, closing at 6.250 HKD, up 2.04% on 36.65 million shares and 231.6 million HKD of turnover (0.85% turnover rate) — a clear pop-and-fade. The day's company flow centred on an AI-driven drug discovery collaboration with Laboratoires Pierre Fabre and a memorandum of understanding with Singapore's A*STAR. The bounce still leaves the shares down 37.44% year-to-date, 56.23% below the 14.28 HKD 52-week high set on 13 January, though 11.6% above the 5.60 HKD low of 22 October; price sits above the 6.147 HKD MA20 but below the 7.083 HKD MA60. While the 22 October cancellation of 4.882 million repurchased shares came shortly before that 52-week low, the stock now trades on a negative PE of -110.56 and 2.59x PB, and QuantumPharm added 1 million shares at 5.9051 HKD.

  4. Nov, 6

    Hong Kong biotech names pulled back and the HSI opened 392 points lower, and XtalPi traced a spike-and-fade session, dipping to HK$6.06 at 09:42 BJ before spiking to HK$6.22 by 09:59 and then drifting sideways through the afternoon to close at HK$6.12 on 34.7 million shares and HK$213 million of turnover. The operating picture remains weak: Q2 2026 revenue of HK$227.3 million fell 19.8% year on year, the net loss widened to HK$145.5 million, net margin stood at -64.0% and EPS at -HK$0.0356. The stock is down 38.6% year to date and 57.1% below its January 13 52-week high of HK$14.28, and although it has rebounded 9.5% from the October 22 low of HK$5.60, it still trades under its MA20 of HK$6.19 and MA60 of HK$7.12. Though a memorandum of understanding with Singapore's A*STAR plus chairman and QuantumPharm purchases near HK$5.9 offer a counterpoint.

  5. Nov, 5

    XtalPi Holdings rose 4.0% to HK$6.36 in a low-open, high-close session, dipping to HK$6.14 at the open before spiking to HK$6.425 at 11:05 BJ and consolidating through the afternoon on 66.54 million shares worth about HK$421 million, a 1.55% turnover, while the Hang Seng gained 0.43% at midday with biotech leading. Sentiment was supported by a memorandum of understanding with Singapore's Agency for Science, Technology and Research, chairman Wen Shuhao's cumulative purchase of 3.793 million shares, and QuantumPharm's 1 million-share increase at HK$5.9051 each, alongside Guosheng Securities' positive view on the AI-empowered innovation value chain. Fundamentals remain weak though: Q2 2026 revenue fell 19.76% year on year to HK$227.3 million, with a net loss of HK$145.5 million, a -63.99% net margin and EPS of -HK$0.0356; the stock is down 36.34% year to date and 55.46% below its 52-week high of HK$14.28, above the MA20 of HK$6.236 but below the MA60 of HK$7.15, with PB at 2.64 and PE negative.

News

Bullish vs. Bearish — Last 3 Months

54.0k followers · 7 opinions
▲Bullish100%
100% Bullish
  • V
    ValueNvest

    $XTALPI(02228.HK) Thanks, boss. It's really rallying now 👍

  • V
    ValueNvest

    $XTALPI(02228.HK) What's going on? 😂

    Add some position.

    Not investment advice!

0% Bearish

No posts yet